{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05490888",
            "orgStudyIdInfo": {
                "id": "PHIN-001"
            },
            "organization": {
                "fullName": "PharmaIN",
                "class": "INDUSTRY"
            },
            "briefTitle": "Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics",
            "officialTitle": "A Phase 1 Open Label Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PHIN-214 in Adults With Child Pugh A and B Cirrhosis",
            "therapeuticArea": [
                "Other",
                "Gastroenterology"
            ],
            "study": "single-and-multiple-dose-escalation-of-phin-in-child-pugh-a-and-b-liver-cirrhotics"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-01-03",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-10-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-07-28",
            "studyFirstSubmitQcDate": "2022-08-04",
            "studyFirstPostDateStruct": {
                "date": "2022-08-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "PharmaIN",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This single and multiple ascending dose (SAD and MAD) study evaluates PHIN-214, being studied to determine the safety, tolerability, and pharmacokinetics, and establish the maximum tolerated dose of this compound in patients with Child Pugh A and B Cirrhosis.",
            "detailedDescription": "Terlipressin has been shown to reduce portal hypertension, improve renal function, and induce natriuresis in cirrhotic patients with ascites without hepatorenal syndrome (HRS). It is approved in Europe for the treatment of bleeding esophageal varices and HRS type 1 and is usually administered as an IV bolus.\n\nThis study is an open label, First in Human study of PHIN-214. PHIN-214 is a terlipressin derivative administered subcutaneously. It is a partial V1a agonist which is designed to reduce splanchnic blood pooling and portal hypertension. A resultant increase in systemic pressure and renal arterial pressure may increase kidney perfusion and creatinine clearance. As a partial V1a agonist that traffics into the bloodstream from a subcutaneous depot, this derivative is designed to be gentler than terlipressin and has been well tolerated at the injection site, to date.\n\nThis study will evaluate the use of PHIN-214 administered at various dosing levels to establish the maximum tolerated dose in patients with Child Pugh A and B Cirrhosis."
        },
        "conditionsModule": {
            "conditions": [
                "Cirrhosis, Liver",
                "Liver Fibrosis",
                "Ascites Hepatic"
            ],
            "keywords": [
                "Terlipressin",
                "Cirrhosis",
                "Vasoconstrictor",
                "Refractory Ascites"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 48,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "single dose of PHIN-214",
                    "type": "EXPERIMENTAL",
                    "description": "single ascending dose of PHIN-214",
                    "interventionNames": [
                        "Drug: PHIN-214 Subcutaneous injection"
                    ]
                },
                {
                    "label": "multiple daily dosing of PHIN-214",
                    "type": "EXPERIMENTAL",
                    "description": "multiple doses of PHIN-214, daily for 28 days",
                    "interventionNames": [
                        "Drug: PHIN-214 Subcutaneous injection"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "PHIN-214 Subcutaneous injection",
                    "description": "subcutaneous injection(s) with PHIN-214 terlipressin derivative",
                    "armGroupLabels": [
                        "multiple daily dosing of PHIN-214",
                        "single dose of PHIN-214"
                    ],
                    "otherNames": [
                        "Terlipressin derivative"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of dose limiting toxicities",
                    "description": "Incidence of dose limiting toxicities",
                    "timeFrame": "up to sixweeks"
                },
                {
                    "measure": "incidence of stopping criteria",
                    "description": "incidence of stopping criteria",
                    "timeFrame": "up to six weeks"
                },
                {
                    "measure": "incidence of AEs",
                    "description": "incidence of AEs",
                    "timeFrame": "up to six weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "PK of PHIN-214",
                    "description": "plasma concentration of PHIN-214",
                    "timeFrame": "up to six weeks"
                },
                {
                    "measure": "AUC of PHIN-214",
                    "description": "AUC of PHIN-214",
                    "timeFrame": "up to six weeks"
                },
                {
                    "measure": "PK of PHIN-214 metabolite",
                    "description": "plasma concentration of PHIN-214 metabolite",
                    "timeFrame": "up to six weeks"
                },
                {
                    "measure": "AUC of PHIN-214 metabolite",
                    "description": "AUC of PHIN-214 metabolite",
                    "timeFrame": "up to six weeks"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "various exploratory markers of efficacy",
                    "description": "systolic and diastolic blood pressure",
                    "timeFrame": "up to six weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Body mass index within the range 18 to 40 kg/m2 (inclusive) at screening.\n2. Females must be non-pregnant, non-lactating or of non-childbearing potential or using highly efficient contraception for the full duration of the study.\n3. Cirrhosis based on histology or a combination of clinical, radiological, or biochemical and classified as Child-Pugh A or B.\n\nExclusion Criteria:\n\n1. Significant abnormalities in medical history or on physical examination, including: respiratory disease requiring therapy or history of respiratory failure, cardiovascular disease or hypertension, electrocardiogram abnormalities or history of significant EKG abnormalities.\n2. History of diabetes insipidus, syndrome of inappropriate antidiuretic hormone secretion, or any other disorder associated with fluid or sodium imbalance.\n3. Significant kidney disease\n4. Estimated glomerular filtration rate (eGFR by CKD-Epi) \\<60 ml/min/1.73 m2 or Cr \\>2.0 mg/dL.\n5. Uncontrolled hepatic encephalopathy requiring 2 or more medications to manage during the previous 3 months.\n6. Recipient of a transjugular intrahepatic portosystemic shunt (TIPS).\n7. Known positive HIV serology confirmed by HIV viral load.\n8. Subjects with acute infections, including acute viral hepatitis are to be excluded. Subjects with chronic hepatitis B are eligible if treatment regimen is stable \u2265 3 months prior to study inclusion.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Cynthia C Jones",
                    "role": "CONTACT",
                    "phone": "206-568-1450",
                    "phoneExt": "*104",
                    "email": "cjones@pharmain.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Cynthia C Jones",
                    "affiliation": "PharmaIN",
                    "role": "STUDY_CHAIR"
                }
            ],
            "locations": [
                {
                    "facility": "Arizona Liver Health",
                    "status": "RECRUITING",
                    "city": "Chandler",
                    "state": "Arizona",
                    "zip": "85224",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Angie Coste, FNP-C",
                            "role": "CONTACT",
                            "phone": "480-470-4000",
                            "email": "acoste@azliver.com"
                        },
                        {
                            "name": "Naim Alkhouri, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.30616,
                        "lon": -111.84125
                    }
                },
                {
                    "facility": "Tandem Clinical Research",
                    "status": "RECRUITING",
                    "city": "Marrero",
                    "state": "Louisiana",
                    "zip": "70072",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Chad Bordelon",
                            "role": "CONTACT",
                            "phone": "504-934-8424",
                            "email": "Cbordelon@tandemclinicalresearch.com"
                        },
                        {
                            "name": "Gary Reiss, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.89937,
                        "lon": -90.10035
                    }
                },
                {
                    "facility": "Mayo Clinic",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Douglas Simonetto, MD",
                            "role": "CONTACT",
                            "phone": "507-284-4824",
                            "email": "Simonetto.douglas@mayo.edu"
                        },
                        {
                            "name": "Douglas Simonetto, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                },
                {
                    "facility": "Cleveland Clinic",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Keralee Morey",
                            "role": "CONTACT",
                            "phone": "216-215-0808",
                            "email": "moreyk@ccf.org"
                        },
                        {
                            "name": "Christina Lindenmeyer, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Texas Liver Institute",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78215",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Eric Lawitz, MD",
                            "role": "CONTACT",
                            "phone": "210-253-3426",
                            "email": "Lawitz@txliver.com"
                        },
                        {
                            "name": "Eric Lawitz, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008103",
                    "term": "Liver Cirrhosis"
                },
                {
                    "id": "D000005355",
                    "term": "Fibrosis"
                },
                {
                    "id": "D000001201",
                    "term": "Ascites"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M8485",
                    "name": "Fibrosis",
                    "asFound": "Cirrhosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11103",
                    "name": "Liver Cirrhosis",
                    "asFound": "Cirrhosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4509",
                    "name": "Ascites",
                    "asFound": "Ascites",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077585",
                    "term": "Terlipressin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000959",
                    "term": "Antihypertensive Agents"
                },
                {
                    "id": "D000014662",
                    "term": "Vasoconstrictor Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M17409",
                    "name": "Vasoconstrictor Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M11110",
                    "name": "Liver Extracts",
                    "relevance": "LOW"
                },
                {
                    "id": "M1846",
                    "name": "Terlipressin",
                    "asFound": "Medical Imaging",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4277",
                    "name": "Antihypertensive Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "VaCoAg",
                    "name": "Vasoconstrictor Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "AnAg",
                    "name": "Antihypertensive Agents"
                }
            ]
        }
    },
    "hasResults": false
}